Manufacturers announce launch of lusutrombopag
Lusutrombopag, a thrombopoetin receptor agonist, was recently granted market authorisation for thrombocytopenia in people with chronic liver disease needing a planned invasive procedure on the basis of the results of the L-PLUS 1 and L-PLUS 2 trials.
Source:
PharmaTimes
Resource links:
SPS commentary:
It was approved for use in this indication on the NHS in England by NICE in January this year (TA617).